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ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disturbances that
includes simple steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and
liver cancer. NAFLD affects individuals that consume the typical Western diet consisting
of high levels of fats and carbohydrates. The increase in circulating free fatty acids,
palmitate and oleate, or lipopolysaccharides (LPS), induce oxidative stress and proinflammatory cytokine production in the liver, which all contribute to NAFLD progression.
In this study, we are evaluating the mRNA expression of genes associated with fatty acid
oxidation (FAO) and the protein expression of pro-inflammatory cytokines related to
NAFLD using the HepG2 human liver hepatocellular carcinoma cells exposed to
palmitate/oleate or LPS. The treatment of sodium butyrate (NaB) or sodium propionate
(NaP) was used to relieve oxidative stress and inflammation in liver cells. The quantitative
real-time polymerase chain reaction (qRT-PCR) results show that NaP or NaB, were able
to promote FAO, regulate lipolysis, and reduce reactive oxygen species production by
significantly increasing the mRNA expression of peroxisome proliferator-activated
receptor gamma coactivator 1 alpha (PGC-1α), peroxisome proliferator-activated
receptor

alpha

(PPARα),

adipose

triglyceride

lipase

(ATGL),

carnitine

palmitoyltransferase 1 alpha (CPT1α), fibroblast growth factor 21 (FGF21), and
uncoupling protein 2 (UCP2) in HepG2 cells. Together, NaP and NaB may produce
synergistic effects by significantly increasing CPT1α, PPARα, and UCP2 mRNA
expression in LPS-induced HepG2 cells and by significantly increasing CPT1α and ATGL
mRNA expression in palmitate/oleate-induced HepG2 cells. Only NaP treatment may

vii

have the ability to reverse hepatic steatosis and increase whole-body energy expenditure
by significantly increasing FGF21 mRNA expression in palmitate/oleate-induced HepG2
cells. The ELISA results reveal that only LPS significantly increased Tumor Necrosis
Factor alpha (TNF-α) expression in HepG2 cells. At the same time, NaP alone or in
combination with NaB significantly decreased TNF-α expression in LPS-induced HepG2
cells. The expression of IL-8 in both models showed no significant differences in all
treatments. The Western blot analysis of CPT1α protein expression increased by NaP
alone or in combination with NaB in the palmitate/oleate model. In conclusion, this study
shows promising results for the use of NaP and NaB as a potential new therapy in NAFLD.

viii

CHAPTER 1. LITERATURE REVIEW
1.1.

Non-Alcoholic Fatty Liver Disease Overview
The Western diet often consists of the high consumption of fats and carbohydrates,

which leads to a caloric surplus and multiple metabolic diseases such as non-alcoholic
fatty liver disease (NAFLD). This disease is the accumulation of fat build up in the liver
with little to no consumption of alcohol and is the most common chronic liver disease
around the world [1]. The liver is a multifunctional organ and is a principal regulator of
lipids in the body [2]. However, when the liver’s weight is 5-10% fat, it is considered a fatty
liver which causes the increase of free fatty acids, oxidative stress, and subsequently
inflammation and fibrosis. NAFLD affects around 35% of the general population and 76%90% of disease-specific groups, such as obesity and diabetes [1]. The rising prevalence
of NAFLD has made it the second most common cause of liver transplantation in the
United States [3]. NAFLD is strongly associated with obesity, cardiovascular disease
(CVD), including coronary heart disease and stroke, and metabolic syndrome, including
insulin resistance, type 2 diabetes mellitus, hypertension, and dyslipidemia [4]. The
continuum of NAFLD starts as fat accumulation in the liver, then inflammation and
scarring that leads to non-alcoholic steatohepatitis (NASH), and lastly, cirrhosis occurs in
which scar tissue replaces the liver cells.
The prevalence of NAFLD is difficult to diagnosis since patients are usually
asymptomatic until they develop cirrhosis [5]. The diagnosis is often due to incidental
elevations of serum alanine transaminase (ALT) and aspartate aminotransferase (AST)
[5]. The gold standard for quantitating the stages of NAFLD is liver biopsy but can be
costly, cause sampling error, and increases the chance of complications [5]. The main
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pathologic classifications of NAFLD are Matteoni’s, Brunt’s, Kleiner’s classification with
the NAFLD Activity Score (NAS), Fatty Liver Inhibition of Progression (FLIP) algorithm
with Steatosis Activity, and Fibrosis (SAF) Score [6]. Currently, NAS is the most
commonly used examination in clinical trials [6]. However, there are many limitations,
such as high variability among pathologists, poor correlation with metabolic risk factors,
and the inability to predict fibrosis progression [7, 8]. Imaging methods are the most widely
used non-invasive techniques for the diagnosis of NAFLD [6]. Ultrasonography is the
most common method because of its safety, low cost, and ability to detect if a liver has
more than 30% fat [6]. The main limitation of this method is the inability to differentiate
steatosis from fibrosis [6].
1.2.

Molecular Mechanisms in Non-Alcoholic Fatty Liver Disease
The liver is an essential organ in lipid metabolism and a central regulator of lipid

homeostasis [9]. The liver is responsible for the synthesis of new fatty acids and their
export and distribution to other tissues, as well as their use as energy substrates [9].
These processes are regulated by complex interactions between hormones, nuclear
receptors, and transcription factors, which keep hepatic lipid homeostasis under control
[10]. The disturbance of one or more of these pathways may cause the retention of fat
within the liver, which can cause the development of NAFLD [9]. Hepatic fat build up
results from an imbalance between lipid acquisition and lipid disposal, which includes four
major pathways: uptake of circulating fatty acids, de novo lipogenesis (DNL), fatty acid
oxidation (FAO), and export of lipids in very low density lipoproteins (VLDL) [9].
The uptake of circulating fatty acids by the liver is predominately reliant on fatty
acid transport proteins (FATP), cluster of differentiation 36 (CD36), and caveolins located
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inside the hepatocyte plasma membrane [11, 12]. The two main FATP isoforms found in
the liver are FATP2 and FATP5 [12]. The fatty acid translocase protein, CD36, transports
long-chain fatty acids and is controlled by peroxisome proliferator-activated receptorgamma (PPARγ), pregnane X receptor, and liver X receptor [9]. The caveolins are
membrane proteins that contribute to lipid trafficking and the creation of lipid droplets [12].
After uptake of fatty acids, hydrophobic fatty acids must be transferred between different
organelles by specific fatty acid-binding proteins (FABP) such as FABP1 because they
cannot diffuse freely in the cytosol [11]. FABP1 is the predominant isoform in the liver and
helps with the storage, transportation, and utilization of fatty acids and their acyl-CoA
derivatives [11, 12].
The DNL pathway allows the liver to create new fatty acids from acetyl-CoA [9].
First, acetyl-CoA is turned into malonyl-CoA by acetyl-CoA carboxylase (ACC), and
malonyl-CoA is changed into palmitate by fatty acid synthase (FASN) [9]. New fatty acids
may undergo a series of desaturation, elongation, and esterification steps before being
stored as triglycerides or distributed as VLDL particles [9]. Therefore, increased DNL can
cause NAFLD since saturated fatty acids, such as palmitate, cause inflammation, and
apoptosis [9].
The peroxisome proliferator-activated receptor alpha (PPARα) controls the FAO
pathway and occurs primarily in the mitochondria, which generates adenosine
triphosphate (ATP), mainly when circulating glucose levels are low [9]. In mammalian
cells, the peroxisomes, mitochondria, and cytochromes mediate FAO [13, 14]. In the outer
mitochondrial membrane, carnitine palmitoyltransferase 1 alpha (CPT1α) facilitates the
entry of fatty acids into the mitochondria; however, mitochondria cannot oxidize very long
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chain fatty acids and preferably metabolize via peroxisomal beta (β)-oxidation [15, 16].
The activation of PPARα induces the transcription of a range of genes related to FAO in
the mitochondria (medium- and long-chain acyl-CoA dehydrogenases), peroxisomes
(acyl-CoA oxidase (ACOX) 1 and enoyl-CoA hydratase), and cytochrome-mediated
(CYP4A1 and CYP4A3) [13, 16-18]. Oxidative damage and lipid oxidation to
mitochondrial DNA diminish mitochondrial function, creating a vicious cycle to aggravate
mitochondrial dysfunction and oxidative stress [16].
Oxidative stress causes the imbalance between the factors that generate reactive
oxygen species (ROS) and those that protect the antioxidant system, which leads to
structural modifications of biomolecules, loss of cell signaling and gene expression
control, and apoptosis [19-22]. The induction of oxidative stress resulting from
mitochondrial oxidation of fatty acids leads to lipid peroxidation, advanced glycation end
products (AGEs), and chronic inflammation, which are involved in the progression of
NAFLD [23]. AGEs are molecules produced by in vivo glycation and oxidation or can
occur in foods that reach elevated temperatures, such as frying and grilling [24]. Glycation
occurs when reducing sugars or oxidized lipids react with the epsilon (ε)-side of amino
acids in proteins, amino phospholipids, or nucleic acids without enzymatic regulation and
are the primary cause of internal and external protein damage [23]. The formation of
unstable Schiff bases in glycation undergoes rearrangements, which generates Amadori
products that make the structure more stable and are the first products of the Maillard
reaction [23]. Amadori products give rise to AGEs due to their reactive carbonyl groups
that condense with primary amino groups (Figure 1.1.) [23].
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Figure 1.1. Formation of AGEs from reducing sugars. Amadori product formed from a
nucleophilic attack on the anomeric carbon of the sugar by lysine. After consecutive
displacements, the intermediate α-dicarbonyl dideoxyinosine will form. The α-dicarbonyl
intermediate undergoes a nucleophilic attack on the carbonyl group by the ε-amine, giving
aldimine, a precursor for cross-linking agent Lysine-Arginine, to form glucosepane. C-1,
Anomeric carbon on sugar; epsilon (ε)-amine, of lysine.
5

Typically, glycation occurs slowly; however, under conditions of lipid peroxidation,
the generation of AGEs increases drastically [23]. AGEs can cross-link with specific
molecules by changing the chemical and biological properties or by interacting with matrix
proteins and specialized receptors such as receptors for advanced glycation end products
(RAGE) [23]. Oxidative stress stimulates AGEs/RAGE interaction by increasing the
production of ROS and activating transcription factors, which lead to local tissue damage
and higher inflammatory responses [23].
The liver has immune cells that try to cope with stress by recruiting cells such as
macrophages or monocytes in response to injury by emitting pro-inflammatory signals,
including cytokines, chemokines, and ROS [23]. The expression of inflammatory
cytokines and chemokines plays a significant role in the pathogenesis of NAFLD [25].
Pathogen-Associated Molecular Patterns (PAMPs) refer to many bacterial products such
as lipopolysaccharide (LPS), derived from the cell wall of gram-negative bacteria, and
other molecules such as peptidoglycans, bacterial lipoprotein flagellins, bacterial RNA
and DNA, which can reach the liver upon disturbance of the intestinal mucosal barrier
and trigger innate immune cells, causing intracellular signaling cascades that intensify
injury [26]. LPS binds to specific receptor-activating toll-like receptors (TLRs) such as
TLR4 and TLR9 and can activate Interleukin (IL)-1β, IL-18, IL-8, IL-6, IL-12, and TNF-α,
which subsequently induce inflammation and fibrosis [26-29].
The last pathway is the export of triglycerides which is the only way to diminish
hepatic lipid content [30]. Fatty acids are hydrophobic and must be packed into watersoluble VLDL particles along with apolipoproteins, cholesterol, and phospholipids before
leaving the liver [9]. VLDL particles form inside the endoplasmic reticulum, where
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apolipoprotein B100 (apoB100) is lipidated via the enzyme microsomal triglyceride
transfer protein (MTTP) [9]. The developing VLDL particle must be further lipidated until
it forms a mature VLDL particle, and this process occurs during transportation to the Golgi
apparatus [31]. The apoB100 is required for VLDL export, while the triglyceride content
varies [32, 33]. Both components, apoB100 and MTTP, are crucial in sustaining hepatic
lipid homeostasis and hepatic VLDL secretion [9]. When the export does not occur, this
results in hepatic lipid overload and intracellular lipid accumulation, which leads to
steatosis, lipotoxicity, liver damage, and fibrosis [9].
1.3.

Risk Factors for Non-Alcoholic Fatty Liver Disease
The primary risk factors for NAFLD include obesity, atherogenic dyslipidemia,

hypertension, insulin resistance (IR) and glucose intolerance, CVD, genetics, and
ethnicity [34]. Many rare genetic conditions can cause dysfunction of the standard
processing of nutrients and lipids inside the liver [35]. Also, ethnicity plays a part in which
Hispanics have the highest prevalence of NAFLD, followed by non-Hispanic whites and
then African Americans [1]. The secondary risk factors include family history, gender, age,
polycystic ovary syndrome, environmental toxins, medications, obstructive sleep apnea
[34]. In terms of heritability, a fatty liver is significantly more common in siblings (59%)
and parents (78%) of children with NAFLD [36]. Men have an increased prevalence of
NASH, and women typically develop the disease later than men do [37]. The major
contributors that cause these risk factors to develop are the Western diet that causes
oxidative stress, inflammation, and gut microbiota changes.
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1.3.1. Western Diet
The rapid increase in the prevalence of obesity, metabolic syndrome, and NAFLD
all relate to the Western diet, which often consists of excessive caloric intake due to the
increased consumption of elevated levels of sugar and fat with a sedentary lifestyle [38].
The liver is a vital organ for protein, fats, and carbohydrate metabolism, catabolism, and
excretion of toxins [39]. Any functional impairment can affect the whole organism, which
can lead to morbidity and mortality [39]. Globally, fructose consumption has increased
over the last decade [39]. Fructose is a monosaccharide that is naturally present in fruit
and honey and has a high sweetness over other sugars [40]. Fructose is also a significant
component in sucrose also known as table sugar, which is a disaccharide of fructose and
glucose, and in high fructose corn syrup (HFCS) which is a mixture of fructose and
glucose monosaccharides [40]. Sucrose and HFCS are considered risk factors for NAFLD
and obesity [39, 40]. Studies in humans show that fructose induces DNL and inhibits fatty
acid oxidation in the liver [41-45]. Glucose is a crucial energy source for the entire body
and is metabolized mainly by glucokinase or hexokinase [40]. Fructose metabolism
occurs mostly in the liver and is principally metabolized by fructokinase [40]. The major
isoform of fructokinase in the liver is fructokinase C, which phosphorylates fructose
quickly and causes a reduction of ATP and intracellular phosphate [40]. The decrease in
intracellular phosphate stimulates the enzyme, adenosine monophosphate (AMP)
deaminase, that changes AMP to inosine monophosphate (IMP), resulting in the
formation of uric acid [40]. The fall in ATP levels causes multiple reactions to occur,
including a brief block in protein synthesis, an induction in oxidative stress, and
mitochondrial dysfunction [46-48]. Fructokinase C is the main enzyme that metabolizes
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fructose in the liver and is highly expressed in the small intestine [40]. The metabolism of
fructose in the intestine results in an altered gut microbiome which increases gut
permeability through the loss of tight junctions [40]. Consequently, endotoxin gets into the
portal vein and triggers the formation of a fatty liver, leading to the progression of NAFLD
[40].
In NAFLD, a fatty liver is the consequence of the excessive build up of various
lipids [49]. Triglycerides are the most common type of lipids in the fatty liver [49]. Palmitic
(C16:0) and oleic (C18:1) acids are the most common FFAs in liver triglycerides [50].
Fatty acids can come from the diet or synthesize in cells through metabolic pathways
such as DNL [2]. Depending on the nutrient and energy environments, fatty acids can be
quickly oxidized in peroxisomes and mitochondria to sustain the cellular bioenergetic
homeostasis [51]. This ability to completely oxidize fatty acids to create energy occurs in
most mammalian cells, but mature red blood cells depend only on glucose utilization to
yield adequate amounts of ATP for survival [52]. There are different types of fatty acids
with specific properties based on chain length and degree of saturation [53]. Palmitic acid,
a saturated long-chain fatty acid, can be produced from the diet or endogenously from
other fatty acids, carbohydrates, and proteins [54]. In autoimmune diseases, palmitic acid
enhances the differentiation of naive T cells into T helper 1 (Th1) and T helper 17 (Th17)
cells, promoting inflammation through activation of the p38 mitogen-activated protein
kinases (MAPK) pathway [55]. Oleic acid, a monounsaturated long-chain fatty acid, is
found naturally in numerous animal and vegetable fats and oils [55].
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1.3.2. Gut Microbiota
A delicate balance between gut microbiota, intestinal epithelial cells, and gut
mucosal system is vital to sustaining intestinal permeability and tissue homeostasis [56].
When the gut microbiota becomes imbalanced inside the body, this refers to gut
dysbiosis. The gut-liver axis is the concept of gut bacteria affecting liver homeostasis from
the interaction between the gastrointestinal tract and the liver [57]. The liver is the first
organ to drain the gut through the portal vein and plays a vital role in host-microbe
interactions [57]. The portal blood contains molecules and nutrients that cross from the
gut to the blood, which makes the liver one of the most exposed organs to intestinal
bacteria and bacterial-derived products (Figure 1.2.) [58]. The disturbances of the gut–
liver axis include gut barrier disruption, bacterial translocation, inflammatory response in
the liver, and changes in the composition of bacterial products [57]. Microbiome-derived
compounds affect the hepatocytes by small molecules that lead to pro-inflammatory
signaling, variations in gene expression, and modifications in metabolism and toxicity [57].
Bile acids in the small intestine promote the release of β-Klotho, a membrane protein, that
affects hepatic synthesis [59]. β-Klotho binds to its receptor, farnesoid X receptor (FXR),
inside the intestinal epithelial cells and travels to the liver through portal vein [57]. The βKlotho binds to fibroblast growth factor receptor 4 (FGFR4) on the surface of hepatocytes
and causes an altered metabolism [57]. Bile acids also stimulate the Takeda G-coupled
receptor 5 (TGR5) on the Kupffer cells, which produce the secretion of pro-inflammatory
cytokines that cause pro-inflammatory signaling to hepatocytes [57]. Peptidoglycan and
LPS, bacterial pattern molecules, signal Toll-like receptor 2 (TRL2), and Toll-like receptor
4 (TRL4) [57]. The short-chain fatty acid, acetate, binds to its receptor G-protein coupled
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receptor 43 (GPCR) GPR43 and alters metabolism, while butyrate acts as a histone
deacetylase (HDAC) inhibitor and regulates gene expression [57]. Phenylacetate has an
unknown mechanism that affects the expression of metabolic genes, FASN and
lipoprotein lipase (LPL), which cause metabolic changes [57]. Lastly, the toxic derivative
of ethanol, acetaldehyde, causes high oxidative stress on the hepatocytes [57].

Figure 1.2. Gut microbiota-derived compounds affecting liver metabolism [57].

The healthy intestinal epithelium is an impenetrable physical barrier that keeps the
host separate from the contents of the gut [57]. Tight junctions are essential regulators of
intestinal permeability that prevent bacteria from entering the intestinal mucosa and
11

bloodstream under physiological conditions [60]. However, regulation becomes
pathological with the disruption of tight junctions and extreme paracellular leakage of nonself antigens to the lamina propria, which leads to the progression of NAFLD and NASH
[57].

Figure 1.3. The intact (A) and disrupted (B) gut barrier.
The gut barrier consists of tight junctional complexes, a mucous layer produced by goblet
cells, antimicrobial resistance facilitated by Paneth cells, and the complex network of
innate and adaptive immune cell populations (Figure 1.3.) [57]. Gut barrier disruption
causes the translocation of LPS from gram-negative bacteria to mucosa and circulation,
12

which initiates or enhances liver inflammation [57]. Multiple clinical and experimental data
have confirmed that LPS significantly contributes to the development of obesity-related
inflammatory liver diseases such as NAFLD and NASH [27, 61].
1.4.

Treatment Options
The two main treatment options for NAFLD are dietary changes and lifestyle

modifications. In some cases, body weight loss is not achievable. Therefore, a few
recommendations include medications and supplements; however, there are multiple
side effects. Unfortunately, the lack of understanding of this disease makes prevention a
challenging option.
1.4.1. Therapeutic Approach
The most common antioxidant used in the treatment of NAFLD progression is
Vitamin E [62]. However, the main concern for administrating vitamin E as a treatment is
the possibility of producing toxic doses and could potentially cause prostatic cancer or a
hemorrhagic stroke [62]. Vitamin E treatment is beneficial for patients with biopsy-proven
NASH who are non-diabetics and should receive a lower dose (300–400 mg/day) [63].
Pioglitazone treatment has been tested on NASH patients with prediabetes or type 2
diabetes and is confirmed to be safe and effective during a 3-year study [64]. The negative
concerns for pioglitazone include prostate or pancreas cancer, fluid retention, weight gain,
and cardiovascular events [62]. Other therapies investigate pentoxifylline (improves
hepatic steatosis), obeticholic acid (improves hepatic steatosis, inflammation, and
fibrosis), orlistat (improves insulin resistance), ursodeoxycholic acid, statins, omega-3
fatty acids, and glucagon-like peptide 1 receptor (GLP1R) agonists (improves hepatic
steatosis) [65]. However, these therapies have shown to give varying and limited benefits.
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1.4.2. Dietary Approach
New opportunities arise for bioactive compounds found in specific foods to address
inflammation in NAFLD. Bioactive fatty acids include a variety of structures, from simple
to complex fatty acids, each playing multiple roles in the body such as cell proliferation,
metabolic homeostasis, and regulation of inflammatory progressions [66, 67]. Bioactive
fatty acids also play a part in biological effects in cell signaling pathways by adjusting lipid
composition [55]. The dietary fatty acid composition is a significant factor in NAFLD
development since 15% of liver triglycerides come from the diet [68]. The diet can expose
the liver to several types of lipids, such as fatty acids, cholesterol, and triglycerides [69].
1.4.2.1. Short-Chain Fatty Acids Significance
Humans lack the necessary enzymes to degrade dietary fibers. These
nondigestible carbohydrates pass into the upper gastrointestinal tract unchanged and are
fermented by anaerobic microbiota in the cecum and the large intestine. The bacterial
fermentation produces multiple groups of metabolites [70]. The major group produced is
short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, which can
differ from one to six carbons (Figure 1.4.) [71].

Figure 1.4. Chemical structures of acetate, propionate, and butyrate
SCFAs play a role in the prevention and treatment of various clinical studies due
to their roles in energy homeostasis, cell proliferation, metabolic homeostasis, and
regulation of inflammatory processes [66, 67]. Butyrate is found in dairy milk, parmesan
14

cheese, and butter but can also be produced by bacteria from resistant starches and
dietary fiber [69, 72]. Butyrate is the primary energy source for colonocytes, and the
remaining fraction goes through the hepatic portal vein to the liver [69]. Butyrate maintains
cellular homeostasis in the intestine, stimulates cell proliferation in normal colonocytes,
and inhibits cell proliferation in cancer cell lines in vitro [73]. Propionate is considered a
substrate for hepatic gluconeogenesis [74]. In the liver, 90% of propionate is absorbed,
and the rest sent into the peripheral blood system [75]. Propionate has beneficial antiinflammatory properties, antihypertensive effects, cardioprotective effects, and influences
T helper cell homeostasis [76].
1.4.2.2. Biosynthesis and Metabolism of Short-Chain Fatty Acids
The microbial transformation of dietary fiber to monosaccharides inside the gut
involves multiple reactions facilitated by the enzymatic supply of specific gut microbiota
(Figure 1.5.) [75]. The result of these fermentations leads to the production of SCFAs.
Acetate comes from pyruvate via the acetyl-CoA route or the Wood-Ljungdahl pathway
[75]. Next, acetate can form through two different branches, the Eastern branch via
reduction of CO2 to formate or the Western branch via reduction of CO2 to CO, which is
united with a methyl group to yield acetyl-CoA [75]. Propionate starts as
phosphoenolpyruvate (PEP) via the succinate pathway, where succinate turns into
methylmalonyl-CoA, and lastly, propionyl-CoA into propionate [75]. Other pathways
include the acrylate pathway where the reduction of lactate produces propionate or the
propanediol pathway, where deoxyhexose sugars such as fucose and rhamnose are
substrates [75]. The third SCFA, butyrate, forms from two molecules of acetyl-CoA,
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yielding acetoacetyl-CoA, which converts to butyryl-CoA via β-hydroxybutyryl-CoA and
crotonyl-CoA [75].

Figure 1.5. Pathways for the biosynthesis of short-chain fatty acids from dietary fiber
Once the generation of SCFAs occurs, they can enter the cells via
monocarboxylate transporters (MCTs), passive diffusion, or exchange with bicarbonate
(HCO3−) via partially oxidized CO2 [77]. A list of all known SCFA transporters is shown in
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Table 1.1. [77]. After transportation, the colonocytes absorb the SCFAs and enter the
citric acid cycle inside the mitochondria to generate ATP and energy for the cells [78]. All
three SCFAs via oxidation enter hepatocytes inside the liver as energy substrates or for
the biosynthesis of glucose, cholesterol, and fatty acids [77].
Table 1.1. Short-Cain Fatty Acid Transporters
Transporter

MCT1
(SLC16A1)

SMCT1
(SLC5A8)

SMCT2
(SLC5A12)

SLC26A3

Localization in the Body
Ubiquitous; apical
membrane and basolateral
membrane of the colonic
epithelium and small
intestine
Entire large intestine (apical
membrane), kidney, and
retina

Neurons

The apical membrane of the
colonic epithelium and small
intestine, kidney, and retina
Apical site of colonocytes
and basolateral site of
colonocytes
Stomach and small intestine

Astrocytes and glia

MCT2
(SLC16A7)

MCT4
(SLC16A3)

OAT7
(SLC22A9)
OAT2
(SLC22A7)

Localization in the
CNS and/or Brain
Ubiquitous; brain
endothelial cells,
astrocytes,
ependymocytes, and
some neurons in rats

The basolateral membrane
of colonic epithelium, small
intestine skeletal muscle,
brain, kidney, placenta,
leukocytes, heart, lung, and
chondrocytes
Liver and sinusoidal
membrane of hepatocytes
Kidney and liver

ND

-Ubiquitous but high
expression in cortex,
hippocampus, and
cerebellum
-Neurons and some
astrocytes in rats
-Ubiquitous but high
expression in cortex,
hippocampus, and
cerebellum
-Astrocytes

SCFA
Substrate
Acetate,
propionate, and
butyrate;
butyrate uptake
involves this
transporter
Acetate,
propionate, and
butyrate;
butyrate faster
than propionate
and acetate
Low affinity for
propionate and
butyrate
Acetate,
propionate, and
butyrate
Low affinity for
acetate,
propionate, and
butyrate

High affinity for
butyrate

ND

Butyrate

ND

Propionate

CNS, central nervous system; MCT, monocarboxylate transporter; ND, not determined;
OAT, organic anion transporter; SCFA, short-chain fatty acid; SMCT, sodium-dependent
monocarboxylate transporter.
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1.4.2.3. Mechanism of Short-Chain Fatty Acids
The role of SCFAs involves cellular signaling pathways and their interaction with
gut-brain pathways, which include immune, endocrine, vagal, and other humoral
pathways (Figure 1.6.) [77].

Figure 1.6. The gut-brain pathways where SCFAs may modify or control brain function.
BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor;
HPA, hypothalamus-pituitary-adrenal; NGF, nerve growth factor; TH1, T helper 1; TH17,
T helper 17; Treg cell, regulatory T cell.

Through the immune pathway, SCFAs can improve barrier integrity by
upregulating the expression of tight junction proteins and increasing transepithelial
electrical resistance (TEER) [77]. SCFAs can also activate free fatty acid receptors
(FFARs) by interacting with intestinal epithelial cells and immune cells or by inhibiting
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HDAC [77]. Histone acetylation begins as a fundamental switch that permits the
interconversion between acetylation and deacetylation [77]. The removal of acetyl groups
of histone tails occurs by HDAC inhibitors, while the additional acetyl groups of histone
tails occur by histone acetyltransferases (HATs) [77]. Many studies report that HDAC
inhibitors are involved in cancer therapy, brain development, and a range of
neuropsychiatric diseases, including depression, schizophrenia, Alzheimer’s disease,
and addiction [79]. Butyrate and propionate are both known to act as HDAC inhibitors
which possess antiproliferative effects, anti-inflammatory properties, reduce insulin
resistance, and stimulate hepatic fatty acid β-oxidation [80, 81]. SCFAs via HDAC
inhibition can also regulate cytokine expression in T cells and the production of Treg [82].
Butyrate is the most investigated SCFA due to its high presence in the gut lumen, and
primary energy source for colonocytes [83]. Normal colonocytes oxidize butyrate,
whereas nuclear extracts from cancer cells accumulate butyrate 3-fold [84]. Therefore,
butyrate can act as an efficient HDAC inhibitor in cancerous cells and a HAT activator in
healthy cells. Through HDAC inhibition, butyrate makes the immune system
hyporesponsive to beneficial commensals by suppressing pro-inflammatory effectors in
lamina propria macrophages [77]. The beneficial health outcomes of using SCFAs
includes their HDAC-inhibiting activity, high abundance (mM range), and energetics of
cells using fatty acids for energy and generation of ATP versus glycolysis.
The endocrine pathway is when SCFAs interact with their receptors on
colonocytes, which induce indirect signaling to the brain by inducing the secretion of gut
hormones such as glucagon-like peptide 1 (GLP1) and peptide YY (PYY) from
enteroendocrine L cells via the systemic circulation or vagal pathways [77].
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These hormones impact learning, memory, and mood [77]. SCFAs can also signal to the
brain by directly activating vagal afferents via FFAR [85]. Propionate can activate GPCRs,
FFAR-2 and FFAR-3, also known as GPR43 and GPR41, respectively [81]. Propionate
has the highest rank order of potency compared to acetate and butyrate in both GPR41
and GPR43 [86]. The mechanism of propionate involves changing invasive phenotypes
to non-invasive phenotypes [87]. GPR41 is in the gut, adipose tissue, and the peripheral
nervous system (PNS), while GPR43 is in adipose tissue, immune cells, and the intestine
[88]. GPR43 releases PYY and GLP-1, affecting satiety and intestinal transit [89]. GPR41
signaling involves propionate-induced intestinal glucogenesis by gut-brain neurocircuitry
[90]. Both propionate and butyrate increase intestinal glucose production; however,
butyrate directly upregulates intestinal glucogenesis genes (G6PC and PCK1), while
propionate does indirectly [91]. Propionate receptor GPR41 is present in the nerve fibers
of the portal vein wall and can send signals to the peripheral and central nervous system
(CNS) areas to induce intestinal gluconeogenesis [77]. Butyrate can signal GPR109A,
which exerts immune-suppressive mechanisms by increasing IL-18 secretion, generating
Treg, and IL-10 producing T cells via signaling [92]. GPR109A is a receptor for nicotinate
(niacin) and facilitates lipid-lowering mechanisms [92]. The signaling of GPR109A is
present on adipocytes, immune cells, and colonocytes [92]. Through the binding of
GPCRs, SCFAs may affect the CNS and PNS, which is a qualification for their assumed
effects on psychological developments.
Lastly, SCFAs can cross the blood-brain barrier (BBB) via monocarboxylate
transporters located on endothelial cells and influence BBB integrity by inhibiting
pathways associated with inflammatory responses [77]. SCFAs also modulate levels of
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neurotrophic factors centrally, via histone acetylation and can contribute to the
biosynthesis of serotonin [83, 93]. Together, the interaction of SCFAs with these gut-brain
pathways can directly or indirectly modulate processes associated with neural
functioning, learning, memory, and mood.
1.5. Research Objective and Hypothesis
NAFLD is the most common cause of chronic liver disease [5]. Unfortunately,
patients are asymptomatic in the early stages, which makes diagnosis difficult [5].
Currently, the only treatment is regular exercise and a healthy diet. The main objective of
this doctoral dissertation research is to evaluate the mechanisms behind sodium butyrate
(NaB) and sodium propionate (NaP), which could potentially serve as bioactive
compounds that relieve oxidative stress and inflammation in NAFLD progression. We
hypothesize that NaP alone, NaB alone, or in combination, will promote FAO and reduce
pro-inflammatory cytokines in HepG2 cells.
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CHAPTER 2. SODIUM PROPIONATE AND SODIUM BUTYRATE PROMOTE FATTY
ACID OXIDATION IN HEPG2 CELLS UNDER OXIDATIVE STRESS

2.1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a series of disturbances that involve
various steps of liver damage including simple steatosis, which is fat accumulation in liver
cells, to non-alcoholic steatohepatitis (NASH), fat build up plus inflammation in liver cells,
that can eventually lead to hepatic fibrosis, cirrhosis, or liver cancer [1]. NAFLD affects
individuals that consume the typical Western diet consisting of high levels of refined
sugars, fats, and other refined carbohydrates such as starch. Consequently, the increase
of circulating free fatty acids (FFAs) as a result of unhealthy white adipose tissue causes
oxidative stress and liver inflammation. Palmitic acid, a saturated fatty acid, and oleic
acid, a monounsaturated fatty acid, are the most abundant FFAs in the diet and fatty liver
[2]. Palmitic acid is in palm oil, meat, dairy products, cocoa butter, olive oil, and breast
milk [3, 4]. Oleic acid is mostly in olive and canola oil but also found in animal fats such
as lard [5].
One important mechanism contributing to the development of NAFLD is gut
dysbiosis, where the imbalance of gut bacteria affects liver homeostasis [6]. The liver is
the first organ to drain the gut through the portal vein and plays a vital role in host-microbe
interactions [6]. The portal blood contains water-soluble molecules and nutrients that
cross from the gut to the blood, which makes the liver one of the most vulnerable organs
to intestinal bacteria and bacterial-derived products [6]. A leaky and inflamed gut can lead
to the translocation of lipopolysaccharide (LPS), which comes from the cell wall of gramnegative bacteria and worsens liver inflammation. The relationship between metabolic
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disorders, inflammation, a Western diet with overconsumption of energy, oxidative stress,
and the changes in gut microbiota might result from LPS exposure [7]. The liver, in
response to the elevated levels of palmitic and oleic acid or LPS, activates the release of
numerous pro-inflammatory cytokines, such as Interleukin (IL)-8, IL-6, and Tumor
Necrosis Factor alpha (TNF-α), within the liver microenvironment [8, 9].
One of the major pathways disrupted in NALFD is fatty acid oxidation (FAO), which
occurs primarily inside the mitochondria and generates adenosine triphosphate (ATP)
[10]. Peroxisome proliferator-activated receptor alpha (PPARα), a transcriptional activator
of hepatic lipid metabolism genes such as carnitine palmitoyltransferase 1 alpha (CPT1α),
controls the FAO pathway [11]. CPT1α is the rate-limiting enzyme of fatty acid beta (β)oxidation because it is involved in getting palmitic acid across the outer mitochondrial
membrane into the mitochondrial matrix [12, 13]. In NAFLD patients, both PPARα and
CPT1α levels significantly decrease in comparison to a healthy liver [14]. Short-chain fatty
acids (SCFAs) such as butyrate and propionate can activate free fatty acid receptors
(FFARs) by inhibiting histone deacetylases (HDAC), leading to greater gene expression
for FAO genes, which stimulates hepatic fatty acid β-oxidation [15]. Many studies report
that HDAC inhibitors possess anti-proliferative effects, anti-inflammatory properties, and
regulate cytokine expression [16-18]. Butyrate is found in butter, parmesan cheese, and
the lipid component of dairy milk, but can also form from resistant starches and dietary
fiber in the large intestine [19, 20]. After absorption of butyrate, colonocytes use it as their
primary source of energy, and the remaining fraction goes through the hepatic portal vein
to the liver [19]. Butyrate has beneficial effects that include anti-inflammatory properties,
increases in mitochondrial activity, prevention of metabolic endotoxemia, increases in
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intestinal barrier function, and helps reduce body weight [20, 21]. Butyrate also has low
systemic toxicity, which makes it an excellent agent for clinical trials. Propionate can
provide energy for epithelial cells and is considered a substrate for hepatic
gluconeogenesis [22]. The liver absorbs about 90 % of propionate, and the rest is sent
into the peripheral systemic blood [14]. Propionate has beneficial anti-inflammatory
properties, anti-hypertensive effects, and cardioprotective effects [23]. Both butyrate and
propionate reduce food intake, weight gain, and high blood sugar [24].
In this study, we are evaluating the mRNA expression of genes associated with
fatty acid metabolism and the protein expression of pro-inflammatory cytokines related to
NAFLD using the HepG2 human liver hepatocellular carcinoma cells exposed to palmitate
and oleate or LPS. The mechanisms behind sodium butyrate (NaB) or sodium propionate
(NaP) could potentially serve as bioactive compounds that relieve oxidative stress and
inflammation in liver cells. We hypothesize that NaB or NaP or in combination will promote
FAO and reduce pro-inflammatory cytokines in HepG2 cells.
2.2. Materials and Methods
2.2.1. Reagents
Radioimmunoprecipitation assay (RIPA) buffer (#89900), protease inhibitors
(#5871S), phosphatase inhibitors (#5870S), Gibco™ fetal bovine serum (FBS)
(#26140079),

phosphate

buffer

solution

(PBS)

(#10010023),

Gibco™

gentamicin/amphotericin solution (#R01510) and Gibco™ 1X minimum essential medium
(MEM) (#11095072), and Ambion® RNAsecure™ (#AM7005)

were obtained from

ThermoFisher Scientific (Waltham, MA). TRl reagent (#T9424), fatty acid free-bovine
serum albumin (BSA) endotoxin-free (#A8806), lipopolysaccharide from Escherichia coli
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O111:B4 (#L4391), penicillin-streptomycin (#P0781), and 1-Bromo-3-chloropropane
(BCP) (#B9673) were obtained from Sigma Aldrich (St. Louis, MO). Sodium palmitate
(#P0007), sodium oleate (#O0057), sodium butyrate (#S0519), and sodium propionate
(#P0512) were purchased from TCI America (Portland, OR).
2.2.2. Palmitate and Oleate Preparation
Stock solutions of 5mM sodium palmitate and 10mM sodium oleate were prepared
in MEM with 10% defatted BSA. Briefly, sodium palmitate was dissolved in PBS and then
heated at 70˚C until completely clear, and quickly added to preheated MEM 37˚C. Sodium
oleate was directly added to preheated MEM. All preparations were filtered and stored at
4˚C.
2.2.3. Sodium Butyrate and Sodium Propionate Preparation
The 100mM stock solutions were prepared for NaB and NaP in PBS.

All

preparations were filtered and stored at 4˚C.
2.2.4. Cell Line and Culture Conditions
The HepG2 human hepatocellular carcinoma cells (ATCC HB-8065, Manassas,
VA)

were

maintained

in

MEM

with

10%

FBS

and

1%

antibiotic

(penicillin/streptomycin/amphotericin) at 37°C in a humidified atmosphere containing 95%
air and 5% CO2. Just before reaching 80% confluence, cells were split (1:6) by
trypsinization into 6, 24, or 96-well plates in MEM with 10% FBS and 1% antibiotic
(penicillin/streptomycin/amphotericin) for 24h. All experimental treatments were
conducted in MEM with 10% heat-inactivated FBS (inactivated by heating for 30 minutes
at 56°C) and 1% antibiotic (penicillin/streptomycin/amphotericin) which was the vehicle
control treatment. Cells were subjected to oxidative stress using LPS from Escherichia
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coli O111:B4 (1ug/ml) in some experiments. In other experiments, cells were preloaded
with a combination of palmitate (0.5mM) and oleate (0.5mM) for 24h. After 24h, cells were
treated with various concentrations of NaB (2, 4mM), NaP (2, 4, and 8mM), or a
combination of NaB (2mM) and NaP (4mM) for another 24h in the presence of LPS or the
combination of palmitate and oleate.
2.2.5. Cell Viability using MTS Assay
The MTS assay (#G3582) was used to test cell viability from Promega (Madison,
WI). The HepG2 cells were plated in a 96-well at 5 × 103 cells per well and treated with
different concentrations of palmitate and oleate combined (0.5, 1, 2mM), LPS (400, 800,
1000 ng/ml), NaP (2, 4, 8mM), and NaB (2, 4, 8mM) for 24h. CellTiter 96® AQueous One
Solution Reagent (100ul) was directly added to each cell culture well, incubated for 1h at
37°C in a humidified atmosphere containing 5% CO2, and then absorbance was recorded
at 490nm using the BioRad Model 680 microplate reader (Hercules, CA). The quantity of
formazan product measured at 490nm absorbance is directly proportional to the number
of living cells in culture. The relative cell viability equation was used to determine the
percentage of living cells.
2.2.6. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
In a 24-well plate, cells were exposed to LPS from Escherichia coli O111:B4
(1µg/ml) or with a combination of palmitate (0.5mM) and oleate (0.5mM) for 24h. After
24h, cells were treated with various concentrations of NaB (2, 4mM), NaP (2, 4, and
8mM), or a combination of NaB (2mM) and NaP (4mM) for another 24h in the presence
of LPS or the combination of palmitate and oleate. After 24h treatment, cell media was
aspirated, and TRI Reagent (500µl) was added to each well. Total RNA was extracted
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from cells using TRI Reagent and purified with the RNeasy Mini Kit (#74104) from Qiagen
(Hilden, Germany). Briefly, cell homogenates were stored at room temperature for 5
minutes. Next, BCP (50µl) was added to each sample to facilitate the separation of
organic (proteins) and aqueous phases (RNA). The samples were shaken by hand
vigorously for 20 seconds, stored at room temperature for 5 minutes, and centrifuged at
12,000 rpm for 15 minutes at 4˚C to clarify phases. The upper aqueous phase containing
total RNA (200µl) was removed, added to ice-cold 100% RNA-free ethanol (220µl), and
loaded onto RNeasy mini spin columns. The columns were washed with RW1 and RPE
buffers to remove DNA and protein. Lastly, columns were transferred to new collection
tubes with RNAsecure (1µl). Total RNA was eluted in RNase-free water (50ul) and stored
at -80˚C until use.
The Qubit RNA BR Assay (#Q10210) and Qubit Fluorometer from ThermoFisher
Scientific (Waltham, MA) were used to quantify RNA concentrations. Reverse
transcriptase and qPCR were conducted sequentially in each reaction with the reverse
PCR primer serving to prime cDNA synthesis using Superscript III Platinum One-Step
Quantitative RT-PCR System (#11732020) from ThermoFisher Scientific (Waltham, MA).
Primer and probe sets were purchased from Applied Biosystems (Pleasanton, CA) (Table
2.1.). Ribosomal Protein L13a (RPL13A) (Taqman® ID Hs04194366_g1, Thermofisher
Scientific, Waltham, MA.) was used as a housekeeping gene. The RT-PCR assay for
each sample was performed each time in duplicate using the protocol for Applied
Biosystems Instruments (7900 HT).
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Table 2.1. Primer and Probe Sequences for qRT-PCR
Gene

Primer and Probe

Sequences

NCBI Reference

ATGL

Forward (5'-3')

CGTGTACTGTGGGCTCATC

NM_020376.3

Reverse (3'-5')

GGACACTGTGATGGTGTTCTTA

Probe

ATGGTGGCATTTCAGACAACCTGC

Forward (5'-3')

GCGTTCTTTGTGACGTTAGATG

Reverse (3'-5')

CGGCCGTGTTAGTAGAGATTTG

Probe

AGAAGGATACAGAAGTGAAGACCCGGA

Forward (5'-3')

GAGTCAAGACATCCAGGTTCC

Reverse (3'-5')

GTATCCGTCCTCAAGAAGCAG

Probe

CCTCAGGGTCAAAGTGGAGCGATC

Forward (5'-3')

CACCAAACCCACAGAGAACA

Reverse (3'-5')

GGGTCAGAGGAAGAGATAAAGTTG

Probe

AAAGAAGTCCCACACACAGTCGCA

Forward (5'-3')

GTCGATTTCACAAGTGCCTTTC

Reverse (3'-5')

CAGGTAAGAATTTCTGCTTTCAGTT

Probe

AACGAATCGCGTTGTGGTGACATCC

Forward (5'-3')

CTACAAGACCATTGCACGAGAGG

Reverse (3'-5')

AGCTGCTCATAGGTGACAAACAT

Probe

CCTCAGGGTCAAAGTGGAGCGATC

CPT1α

FGF21

PGC-1α

PPARα

UCP2

NM_001876.3

NM_019113.4

NM_00145134.1

XM_011530239.2

NM_003355.2

ATGL, adipose triglyceride lipase; CPT1α, carnitine palmitoyltransferase I alpha; FGF21, fibroblast
growth factor 21; NCBI, National Center for Biotechnology Information; PGC-1α, peroxisome
proliferator-activated receptor gamma coactivator l alpha; PPARα, peroxisome proliferator activated
receptor alpha; qPCR, quantitative polymerase chain reaction; UCP2, Uncoupling Protein 2.
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2.2.7. ELISA Analysis of TNF-α and IL-8
The cells were plated in 24-well plates and stimulated with LPS from Escherichia
coli O111:B4 (1ug/ml) or with a combination of palmitate (0.5mM) and oleate (0.5mM).
After 24h, cells were treated with various concentrations of NaB (2, 4mM), NaP (2, 4, and
8mM), or a combination of NaB (2mM) and NaP (4mM) for 24h in the presence of LPS or
the combination of palmitate and oleate. After 24h treatment, culture plates were put on
ice, each well was washed with ice-cold PBS, and cells were scraped into ice-cold RIPA
buffer (300µl) containing protease and phosphatase inhibitors. Samples were pushed
through an ice-cold 20G syringe needle four times to disrupt organelles and centrifuged
at 12,000 rpm for 5 minutes. Cell supernatants were collected and immediately stored at
-80˚C until further use.
The levels of TNF-α (15.6pg/ml-1000pg/ml) (#EK0525) and IL-8 (15.6pg/ml1000pg/ml) (#EK0413) were analyzed using ELISA kits from Boster Bio (Pleasanton, CA)
following manufacturer’s instructions. All samples were diluted using sample diluent
provided in each ELISA kit at 1:25 for the LPS model and 1:50 for the palmitate and oleate
model. The absorbance of each cytokine (pg/ml) was read at 450nm using a BioRad
Model 680 microplate reader (Hercules, CA). Each sample was done in triplicate, and the
protein concentration (pg/ml) of each sample is determined based on the standard curve.
2.2.8. Western Blot Analysis of CPT1α
Cells were plated in 6-well plates and loaded with fat by exposure to a combination
of palmitate (0.5mM) and oleate (0.5mM). After 24h, cells were treated with NaP (8mM)
and the combination of NaB (2mM) and NaP (4mM) for 24h. Total cellular protein was
harvested. Culture plates were put on ice, each well was washed with ice-cold PBS, and
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cells were scraped into ice-cold RIPA buffer (300µl) containing protease and phosphatase
inhibitors. Samples were pushed through an ice-cold 20G syringe needle four times to
disrupt organelles and spun at 12,000 rpm for 5 minutes in a prechilled centrifuge to
remove the insoluble fraction. Cell supernatants were collected and immediately stored
at -80˚C until further use. The protein concentration in samples was quantified using the
bicinchoninic acid assay (BCA) (#23227) from ThermoFisher Scientific (Waltham, MA).
After BCA, to obtain equal sample volumes for loading on gels, RIPA buffer was
added to each 50µg sample. Next, 4X Laemmli sample buffer (#161-0747, Bio-Rad)
mixed with 5% 2-mercaptoethanol (#M6250, Sigma-Aldrich) was added to each sample
and boiled at 100˚C for 5 minutes to denature proteins. Samples were centrifuged and
loaded onto TGX sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) gels (7.5% TGX, Bio-Rad). Gels were run at 100V until the dye line was near the
bottom. Proteins of interest were transferred to nitrocellulose membranes (#1620145, BioRad), then blocked in 5% bovine serum albumin (BSA) in tris buffered saline with 0.1%
tween-20 (TBST) for 1h. The primary antibody for β-actin (#A5316, Sigma) and CPT1α
(#sc-393070, Santa Cruz Biotechnology, Inc.) were prepared in TBS with 4% BSA and
0.5% tween-20 and incubated at room temperature for 3h. The membranes were washed
three times for 5 minutes using TBST, then incubated for 1h with anti-mouse (#AP130P,
Sigma-Aldrich) secondary antibody and washed three times for 5 minutes using TBST.
Visualization of proteins was performed in a dark room using chemiluminescence
(Western Lightning Plus-ECL, PerkinElmer, Waltham, Massachusetts). Densitometric
analyses were done using ImageJ software (National Institutes of Health), and the relative
expression of the target protein versus β-actin was calculated.
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2.2.9. Statistical Analysis
All experiments were performed at least three times. The differences between
samples were analyzed using a one-way analysis of variance (ANOVA) with Tukey’s
honest significant difference (HSD) test. Significance was set at P < 0.05 level. The results
are expressed as mean ± SE. Means with the asterisk (*) symbol indicate significantly
different from the unstimulated control. Means with the pound (#) symbol indicate
significantly different from LPS or palmitate/oleate. All analyses were performed using
SAS 9.4 (SAS Institute, Cary, NC).
2.3. Results
2.3.1. Effect of Palmitate/Oleate, Lipopolysaccharide (LPS), and SCFAs on Cell Viability
To investigate the impact of palmitate/oleate, LPS, NaP, and NaB on cell survival
in HepG2 cells, various concentrations were used for 24h. The results were consistent
with other studies, showing palmitate/oleate at 1mM (80% live cells) and 2mM (70% live
cells) were significantly different from the control (100% live cells). In the LPS model, all
concentrations were not significantly different from the control, which suggests that up to
1ug/ml does not cause significant cell death in HepG2 cells. The concentrations of NaP
and NaB were not significantly different from the control, which suggests that up to 8mM
does not cause significant cell death in HepG2 cells.
2.3.2. FAO and Mitochondrial Related Genes in the LPS Model
The HepG2 cell line was used to investigate the response of NaP and NaB
treatment in the LPS model. The dose of 1ug/ml for LPS has been used by others to
induce inflammation and oxidative stress in HepG2 cells [25-28].
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The treatment of NaB, NaP, or in combination increased the mRNA expression of
peroxisome proliferator-activated receptor-γ coactivator (PGC-1α), PPARα, CPT1α, and
uncoupling protein 2 (UCP2).

Figure 2.1. PGC-1α mRNA expression in HepG2 cells alone (control), in the presence of
LPS, or in the presence of LPS and various concentrations of NaB, NaP, or NaB and NaP
mixture. All data were normalized using RPL13α from three independent experiments.
The results are presented as mean ± SE (n=6). *p < 0.05 represents significantly different
from the control; #p < 0.05 represents significantly different from LPS.
PGC-1α is a potent activator of FAO and controls hepatic gluconeogenesis [29]. PGC-1α
expression was significantly increased in NaP 4mM by 1.49-fold in comparison to LPS
and was significantly increased in NaP 8mM by 1.75-fold in comparison to the control and
LPS (Figure 2.1.)
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PGC-1α is also known to control the transcriptional activity of PPARα, an enzyme involved
in lipid oxidation. PPARα was significantly increased in NaB 2mM, NaB 4mM, NaP 4mM,
NaP 8mM, and the combination of NaB 2mM and NaP 4mM by 1.28-fold, 1.33-fold,1.46fold, 1.68-fold, and 1.54-fold, respectively in comparison to LPS, while NaP 8mM and the
combination of NaB 2mM and NaP 4mM was significantly different from the control
(Figure 2.2.).

Figure 2.2. PPARα mRNA expression in HepG2 cells alone (control), in the presence of
LPS, or in the presence of LPS and various concentrations of NaB, NaP, or NaB and NaP
mixture. All data were normalized using RPL13α from three independent experiments.
The results are presented as mean ± SE (n=6). *p < 0.05 represents significantly different
from the control; #p < 0.05 represents significantly different from LPS.
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PPARα is also a transcriptional activator of CPT1α, which was significantly increased in
NaB 2mM by 1.24-fold, NaB 4mM by 1.21-fold, and the combination of NaB 2mM and
NaP 4mM by 1.37-fold in comparison to LPS (Figure 2.3.). However, there were no
significant differences seen in CPT1α among all treatments against the control.

Figure 2.3. CPT1α mRNA expression in HepG2 cells alone (control), in the presence of
LPS, or in the presence of LPS and various concentrations of NaB, NaP, or NaB and NaP
mixture. All data were normalized using RPL13α from three independent experiments.
The results are presented as mean ± SE (n=6). *p < 0.05 represents significantly different
from the control; #p < 0.05 represents significantly different from LPS.

UCP2, a mitochondrial protein, is a regulator of mitochondrial reactive oxygen species
(ROS) production and plays a role in reducing ROS [12].
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The upregulation of UCP2 was significantly increased in NaB 2mM, NaB 4mM, NaP 4mM,
NaP 8mM, and a combination of NaB 2mM and NaP4mM by 2.15-fold, 2.51-fold, 1.88fold, 2.18-fold, and 2.55-fold, respectively against the control and LPS; however, NaP
4mM was not significantly different from the control (Figure 2.4.).

Figure 2.4. UCP2 mRNA expression in HepG2 cells alone (control), in the presence of
LPS, or in the presence of LPS and various concentrations of NaB, NaP, or NaB and NaP
mixture. All data were normalized using RPL13α from three independent experiments.
The results are presented as mean ± SE (n=6). *p < 0.05 represents significantly different
from the control; #p < 0.05 represents significantly different from LPS.

2.3.3. FAO and Mitochondrial Related Genes in the Palmitate/Oleate Model
The oxidative stress and inflammation induced by palmitate/oleate was rescued by
NaP and NaB treatment by upregulating mRNA expression of adipose triglyceride lipase
(ATGL), PPARα, CPT1α, and fibroblast growth factor 21 (FGF21).
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ATGL is a key lipase in the liver. The treatments of NaB 2mM, NaB 4mM, NaP 4mM, NaP
8mM, and the combination of NaB 2mM and NaP 4mM by 1.80-fold, 2.99-fold,1.43-fold,
2.21-fold, and 2.55-fold, respectively, were significantly different in comparison to the
control and palmitate/oleate (Figure 2.5.).

Figure 2.5. ATGL mRNA expression in HepG2 cells alone (control), in the presence of
palmitate/oleate, or in the presence of palmitate/oleate and various concentrations of
NaB, NaP, or NaB and NaP mixture. All data were normalized using RPL13α from three
independent experiments. The results are presented as mean ± SE (n=6). *p < 0.05
represents significantly different from the control; #p < 0.05 represents significantly
different from palmitate/oleate.
ATGL also plays a role in PPARα signaling [30, 31]. The expression of PPARα was
significantly increased in NaB 2mM, NaP 4mM, and NaP 8mM by 1.24-fold, 1.53-fold,
and 1.74-fold, respectively, in comparison to palmitate/oleate (Figure 2.6.).
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The treatment of NaP 4mM and NaP 8mM was significantly different from the control. The
rest of the treatments were not significantly different against the control or
palmitate/oleate.

Figure 2.6. PPARα mRNA expression in HepG2 cells alone (control), in the presence of
palmitate/oleate, or in the presence of palmitate/oleate and various concentrations of
NaB, NaP, or NaB and NaP mixture. All data were normalized using RPL13α from three
independent experiments. The results are presented as mean ± SE (n=6). *p < 0.05
represents significantly different from the control; #p < 0.05 represents significantly
different from palmitate/oleate.
The expression of CPT1α was significantly increased by 2.25-fold in NaP 8mM and in the
combination of NaB 2mM and NaP 4mM by 2.30-fold in comparison to the control and
palmitate/oleate (Figure 2.7.).
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Figure 2.7. CPT1α mRNA expression in HepG2 cells alone (control), in the presence of
palmitate/oleate, or in the presence of palmitate/oleate and various concentrations of
NaB, NaP, or NaB and NaP mixture. All data were normalized using RPL13α from three
independent experiments. The results are presented as mean ± SE (n=6). *p < 0.05
represents significantly different from the control; #p < 0.05 represents significantly
different from palmitate/oleate.

FGF21 expression, in comparison to the control and palmitate/oleate, were significantly
upregulated in NaP 2mM and NaP 4mM by 1.97-fold and 2.21-fold, respectively (Figure
2.8.). However, NaP 8mM and the combination of NaB 2mM and NaP 4mM were
undetermined and excluded from the results.
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Figure 2.8. FGF21 mRNA expression in HepG2 cells alone (control), in the presence of
palmitate/oleate, or in the presence of palmitate/oleate and various concentrations of
NaB, NaP, or NaB and NaP mixture. All data were normalized using RPL13α from three
independent experiments. The results are presented as mean ± SE (n=6). *p < 0.05
represents significantly different from the control; #p < 0.05 represents significantly
different from palmitate/oleate.
2.3.4. Expression of TNF-α and IL-8 Levels
The protein levels of TNF-α and IL-8, released from LPS-stimulated or
palmitate/oleate-stimulated HepG2 cells were determined using ELISA. LPS is a potent
inducer of TNF-α and was significantly increased (2112 pg/ml) in comparison to the
control (1644 pg/ml) (Figure 2.9.).
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All the treatments of NaB and NaP were not significantly different from the control in the
LPS model. However, in comparison to LPS (2112 pg/ml), the treatment of NaP 8mM
(1400 pg/ml) and the combination of NaB 2mM and NaP 4mM (1285 pg/ml) had
significantly decreased TNF-α expression.

Figure 2.9. TNF-α levels in HepG2 cells alone (control), with LPS, or in combination with
various concentrations of NaB, NaP, or NaB and NaP. TNF-α levels were measured by
ELISA. The results are presented as mean ± SE (n=3). *p < 0.05 represents significantly
different from control; #p < 0.05 represents significantly different from LPS.
In the palmitate/oleate model, the levels of TNF-α in all treatments were not significantly
different from the control (Figure 2.10.).

47

IL-8, also called neutrophil-activating peptide-1 or SCYB8, is a tissue-derived peptide
secreted in response to stimulation by TNF-α.

Figure 2.10. TNF-α levels in HepG2 cells alone (control), with palmitate/oleate, or in
combination with various concentrations of NaB, NaP, or NaB and NaP. TNF-α levels
were measured by ELISA. The results are presented as mean ± SE (n=3). *p < 0.05
represents significantly different from control; #p < 0.05 represents significantly different
from palmitate/oleate.

IL-8 levels in the LPS model showed no significant differences among all treatments. The
two treatments, NaB 2mM (244 pg/ml) and NaB 4mM (262 pg/ml), were able to reduce
IL-8 levels more effectively, however were not statically significant in comparison to the
control (534 pg/ml) or LPS (654 pg/ml) (Figure 2.11.).
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Figure 2.11. IL-8 levels in HepG2 cells alone (control), with LPS, or in combination with
various concentrations of NaB, NaP, or NaB and NaP. IL-8 levels were measured by
ELISA. The results are presented as mean ± SE (n=3). *p < 0.05 represents significantly
different from control; #p < 0.05 represents significantly different from LPS.
In the palmitate/oleate model, like the LPS model, IL-8 levels showed no significant
differences among all treatments (Figure 2.12.). The two treatments, NaB 4mM (1074
pg/ml) and the combination of NaB 2mM and NaP 4mM (945 pg/ml), were able to lower
IL-8 levels more successfully than all other treatments, however were not considered
statically significant in comparison to the control (1461 pg/ml) or palmitate/oleate (1877
pg/ml.
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Figure 2.12. IL-8 levels in HepG2 cells alone (control), with palmitate/oleate, or in
combination with various concentrations of NaB, NaP, or NaB and NaP. IL-8 levels were
measured by ELISA. The results are presented as mean ± SE (n=3). *p < 0.05 represents
significantly different from control; #p < 0.05 represents significantly different from
palmitate/oleate.
2.3.5. Effects of NaP and NaB on Carnitine Palmitoyltransferase 1 alpha (CPT1α) Levels
One of the key proteins in FFA metabolism is CPT1α. Therefore, protein levels of
CPT1α were studied in palmitate and oleate-stimulated HepG2 cells by Western blotting.
The results indicated that CPT1α, which is the rate-limiting enzyme of fatty acid βoxidation, increased.
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Figure 2.13. Western blot results of CPT1α levels in HepG2 cells alone (control), with
palmitate/oleate (P/O), NaP 8mM (NaP8) with P/O, or NaB 2mM and NaP 4mM
(NaB2/NaP4) with P/O. A) Protein levels of CPT1α and β-actin visualized by
chemiluminescence. B) Densitometric analysis of the bands was performed using ImageJ
software, and relative expression of CPT1α versus β-actin was calculated.
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The protein levels of CPT1α in the palmitate/oleate model were increased by NaP 8mM
and the combination of NaB 2mM and Nap 4mM (Figure 2.13.).
2.4. Discussion
In this study, we investigated two major risk factors that lead to the progression of
NAFLD. The combination of palmitate and oleate or LPS, which are generated by the
over consumption of the Western diet. Both risk factors are known to cause gut dysbiosis,
oxidative stress, and inflammation in the liver. We found that mRNA expression levels of
multiple genes involved in FAO were upregulated by NaP and NaB. Studies prove that
propionate and butyrate, but not acetate, act as HDAC inhibitors, which possess
antiproliferative effects, anti-inflammatory properties, and stimulate hepatic FAO [24, 32,
33]. Our results suggest that NaP and NaB can attenuate steatosis and liver injury by
stimulating FAO and mitochondrial related genes, increasing protein expression of
CPT1α, and regulating inflammation by decreasing pro-inflammatory cytokines.
The LPS model, used to represent the consequence of gut dysbiosis, is
significantly elevated in NAFLD human and animal studies [6]. The impact of LPS in
HepG2 cells decreased PGC-1α, UCP2, PPARα, and CPT1α mRNA expression but was
not significantly different from the control. There is evidence that indicates hepatocytes
uptake and detoxifies LPS and could explain why LPS was not able to significantly reduce
FAO related genes [34, 35]. However, we can confirm that LPS caused inflammation in
HepG2 cells through TNF-α expression, which was significantly increased. In the liver,
PGC-1α regulates energy homeostasis, controls gluconeogenesis, and interacts with
genes such as PPARα, which is involved in FAO [29, 36]. Studies show that the dietary
intervention of PGC-1α can prevent and treat metabolic syndrome [19]. Our study shows
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that in vitro, NaP is a novel activator of PGC-1α in the presence of LPS compared to cells
treated with LPS only. The molecular mechanism of NaP could be the ability to stimulate
hepatocyte mitochondrial content and function through PGC-1α activation [29].
Furthermore, NaP, NaB, and in combination, may play protective roles against
mitochondrial oxidative damage since they significantly upregulated UCP2, a transport
protein in the inner mitochondrial membrane, that reduces ROS production [37]. In
NAFLD, FFA overload in the mitochondria increases ROS production and oxidative stress
[38]. The molecular mechanism of NaP and NaB may be the ability to prevent
mitochondrial oxidative stress and hepatic fat accumulation in NAFLD through UCP2
promotion.
We used the combination of palmitate and oleate to represent the fatty acid
composition of Western diets seen in NAFLD patients. The effect of combined palmitate
and oleate only numerically decreased the mRNA expression of FGF21, ATGL, PPARα,
and CPT1α in HepG2 cells but was not significantly different from the control. Palmitate
at high concentrations (> 0.5 mM) causes cytotoxicity via endoplasmic reticulum stress in
hepatocytes, while oleate does not [39, 40]. Studies have shown that when combined,
oleate may protect cells from palmitate-induced cellular stress and apoptosis through
efficient incorporation of fatty acids into triglyceride-rich lipoproteins for export, thus
channeling excess lipids away from toxic pathways [39, 41-44]. Cell viability results
confirmed that the combination of palmitate and oleate was significantly different from the
control, which suggests that palmitate and oleate together can cause cell death but not
significant reductions in FAO. In the liver, FGF21 is highly expressed and increases FAO
by stimulating PGC-1α expression [45]. PGC-1α is a coactivator of PPARα, which controls
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FGF21 at a transcriptional level [45]. In vivo and in vitro studies show that PPARα
agonists can increase FGF21 expression [46-48]. Exogenous FGF21 administration has
been shown to reduce plasma and hepatic triglycerides, reduce body weight, reverse
hepatic steatosis, and increase whole-body energy expenditure in mice fed a high-fat diet
[49]. We show for the first time that only NaP alone was able to significantly increase
FGF21 expression in palmitate and oleate-induced HepG2 cells, which indicates its
potential in stimulating FAO, improving lipid metabolism, and possibly reversing hepatic
steatosis [50, 51]. We speculate that NaP uptake by the liver explains why it has a better
impact than NaB in promoting FGF21 expression since it is highly expressed in the liver.
ATGL is a major lipase in the liver and was significantly increased by NaP, NaB, and in
combination, which suggests these treatments may play a significant role in regulating
lipolysis in palmitate and oleate-stimulated HepG2 cells. ATGL is a rate-limiting enzyme
for intracellular hydrolysis of stored triglycerides and a key regulator of lipid metabolism
[31]. ATGL may serve as a protector of hepatic inflammation through increased PPARα
signaling, when levels of PPARα are low, the risk of developing NAFLD rises [31].
In both models, NaP, NaB, or in combination, significantly increased PPARα and
CPT1α mRNA expression in HepG2 cells. PPARα is a transcription factor that plays a
critical role in hepatic lipid metabolism and regulates fatty acid synthesis and oxidation
[52]. PPARα plays multiple roles in the liver involving FAO, anti-inflammatory, and antifibrotic effects [45, 52, 53]. PPARα agonists have been considered effective treatments
for NAFLD due to their lipid-lowering effects [54]. The treatment of NaP, NaB, or in
combination stimulated FAO, and possibly produced anti-inflammatory and anti-fibrotic
effects through the significant upregulation of PPARα in both experiments. Additionally,
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PPARα activates the expression of CPT1α, which leads to increased FAO [53, 55]. In the
outer mitochondrial membrane, CPT1α is the primary regulatory enzyme involved in
mitochondrial β-oxidation. Therefore, NaP, NaB, or in combination may play a role in
regulating mitochondrial β-oxidation through CPT1α upregulation.
This study found that LPS or palmitate/oleate activates inflammation in HepG2
cells by stimulating pro-inflammatory cytokines TNF-α and IL-8. In a longitudinal analysis,
high serum TNF-α levels in patients were associated with the development of NAFLD
[56]. TNF-α is a major proinflammatory cytokine that causes triglyceride accumulation,
oxidative stress, hepatocyte cell death, and hepatic steatosis [57-59]. In response to TNFα stimulation, IL-8 is produced [60]. IL-8 is a chemokine that acts as a chemical signal
attracting neutrophil migration to the site of inflammation [61]. These pro-inflammatory
cytokines are known to stimulate further liver inflammation and damage. Therefore,
decreasing TNF-α and IL-8 is an important step in preventing the development of NAFLD.
Our findings suggest that LPS causes more inflammation than palmitate/oleate in HepG2
cells through the significant increase of TNF-α expression. Other studies confirm that LPS
significantly increases TNF-α levels in HepG2 cells [25, 62, 63]. All treatments, including
LPS and palmitate/oleate, showed no significant differences in IL-8 expression. However,
other studies have shown that LPS and palmitate induce IL-8 in HepG2 cells [28, 59, 63,
64]. In both models, the treatments of NaP, NaB, and in combination may exert antiinflammatory properties by regulating pro-inflammatory cytokines, TNF-α and IL-8,
through HDAC inhibition since all treatments were not significantly different from the
control. Propionate and butyrate are known to regulate cytokine expression through
HDAC inhibition [32, 65].
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The protein expression of CPT1α increased in the palmitate/oleate model. The two
treatments, NaP (8mM) and NaB (2mM) combined with NaP (4mM) were used based on
the mRNA results. CPT1α catalyzes the transfer of long-chain acyl group of the acyl-CoA
ester to carnitine, which transports fatty acids into the mitochondrial matrix for β-oxidation.
Therefore, NaP alone or, in combination with NaB, has the potential to increase FAO by
permitting the mitochondrial entry of FFA through the increase of CPT1α protein levels
and mRNA expression.
2.5. Conclusion
NAFLD is one of the most common causes of liver dysfunction. The increase in
circulating FFAs, palmitate and oleate, or gut-derived bacterial endotoxin, LPS, in the liver
induces oxidative stress and pro-inflammatory cytokine production, which all contribute
to NAFLD disease progression. In this study, we provide evidence that NaP, NaB, or in
combination, have protective effects on palmitate/oleate- or LPS-induced cellular
steatosis in HepG2 cells. LPS activates greater inflammation than palmitate/oleate by
significantly increasing TNF-α expression in HepG2 cells. The treatment of NaP or NaB
was able to promote FAO, regulate lipolysis, and reduce ROS production through the
significant upregulation of PGC-1α, PPARα, ATGL, CPT1α, FGF21, and UCP2 mRNA
expression in HepG2 cells. Together, NaP and NaB may produce synergistic effects by
significantly increasing CPT1α, PPARα, and UCP2 mRNA expression in LPS-induced
HepG2 cells and by significantly increasing CPT1α and ATGL mRNA expression in
palmitate/oleate-induced HepG2 cells. Only NaP treatment may have the ability to
reverse hepatic steatosis and increase whole-body energy expenditure by significantly
increases FGF21 mRNA expression in palmitate/oleate-induced HepG2 cells.
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The protein expression of CPT1α was increased by NaP (8mM) and the combination of
NaB (2mM) and NaP (4mM) in the palmitate/oleate model. The study shows promising
results for the use of SCFAs, NaP and NaB, as a potential therapy in NAFLD. We suggest
further investigation with NaP and NaB therapy in animal and human clinical trials be
tested.
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CHAPTER 3. SUMMARY AND CONCLUSIONS

NAFLD is the most common chronic liver disease in the United States and
continues to rise every year. The progression of NAFLD is caused by a combination of
the Western diet with a sedentary lifestyle, which causes the increase of FFAs, palmitate
and oleate, or gut-derived bacterial endotoxin, LPS, to circulate inside the liver.
Consequently, the increase of palmitate, oleate, and LPS causes oxidative stress and
inflammation in the liver.
Many studies have shown the benefits of SCFAs in the prevention and treatment
of various metabolic diseases. The purpose of this dissertation was to evaluate the
mechanisms behind NaP and NaB in FAO and explore their potential benefits in relieving
oxidative stress and inflammation in liver cells. The mRNA expression of genes
associated with fatty acid metabolism and the protein expression of CPT1α and proinflammatory cytokines related to NAFLD using the HepG2 human liver cancer cell line
were exposed to palmitate/oleate or LPS.
Our results suggest that NaP, NaB, or in combination, will promote FAO, regulate
lipolysis, and reduce ROS production while regulating pro-inflammatory cytokines in
HepG2 cells. Together, NaP and NaB may produce synergistic effects in both models by
effectively increasing FAO. However, only NaP treatment may have the ability to reverse
hepatic steatosis and increase whole-body energy expenditure. This study shows the
beneficial uses of NaP and NaB in NAFLD treatment. Therefore, future studies in NaP
and NaB therapy in animal and human models need to be investigated to validate our
results.
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